Skip to main content
Recombinant human thrombomodulin inhibits arterial neointimal hyperplasia after balloon injury
Information Technology Publications and Presentations
  • Jian-ming Li, University of Massachusetts Medical School
  • Michael J. Singh
  • Mazen Itani
  • Calin A. Vasiliu, UMass Memorial Health Care
  • Gregory M. Hendricks, University of Massachusetts Medical School
  • Stephen P. Baker, University of Massachusetts Medical School
  • John E. Hale
  • Michael J. Rohrer
  • Bruce S. Cutler, University of Massachusetts Medical School
  • Peter R. Nelson
UMMS Affiliation
Information Services, Academic Computing Services; Department of Cell Biology; Department of Surgery
Publication Date
Document Type
Angioplasty, Balloon; Animals; Femoral Artery; Humans; Hyperplasia; Male; Microscopy, Electron; Microscopy, Electron, Scanning; Rabbits; Recombinant Proteins; Thrombomodulin; Thrombosis; Time Factors; Tunica Intima; Vascular Patency

OBJECTIVE: Smooth muscle cell proliferation is a major pathophysiologic factor in injury-induced neointimal hyperplasia and recurrent stenosis. We have demonstrated that recombinant human thrombomodulin (rTM) inhibits thrombin-induced arterial smooth muscle cell proliferation in vitro. The purpose of this study was to investigate the effect of rTM on neointimal hyperplasia in vivo.

METHODS: A rabbit femoral artery balloon injury model was used. Bilateral superficial femoral arteries were deendothelialized with a 2F arterial embolectomy catheter. rTM (145 microg/kg; 2.0 microg/mL in circulation) or Tris-hydrochloride vehicle control was administered intravenously during the procedure, then either discontinued (group A) or administered twice daily for an additional 48 hours (group B). Rabbits were euthanized at 4 days and at 1, 2, and 4 weeks, and femoral artery specimens were prepared with in situ perfusion fixation and paraffin embedding. Luminal, intima, media, and whole artery areas were quantitated with digital imaging computerized planimetry. Intima-media and lumen-whole artery ratios were calculated. The injury-induced inflammatory reaction was also evaluated with light microscopy, scanning and transmission electron microscopy, and immunohistochemical and immunohistofluorescence staining.

RESULTS: In the buffer control group, neointimal hyperplasia after femoral artery balloon injury was evident at 2 weeks, and was pronounced at 4 weeks (PCONCLUSIONS: Systemic intravenous administration of rTM significantly decreases neointimal hyperplasia and improves patency in the rabbit femoral artery after balloon injury. In addition to exhibiting antithrombotic and antiproliferative effects, rTM may also invoke an anti-inflammatory mechanism, and may alter vascular remodeling in a multidimensional role to inhibit recurrent stenosis after arterial injury.

DOI of Published Version
J Vasc Surg. 2004 May;39(5):1074-83. Link to article on publisher's site
Related Resources
Link to article in PubMed
PubMed ID
Citation Information
Jian-ming Li, Michael J. Singh, Mazen Itani, Calin A. Vasiliu, et al.. "Recombinant human thrombomodulin inhibits arterial neointimal hyperplasia after balloon injury" Vol. 39 Iss. 5 (2004) ISSN: 0741-5214 (Print)
Available at: